12 March 2019, Munich, Germany – On 8–9 May 2019, decision makers from biotech, pharma and finance will come together in Munich for the 12th BioVaria to learn about commercially attractive academic inventions and initiate partnerships with research teams, entrepreneurs and technology transfer professionals from all over Europe.
66 peer-selected, patent-protected technologies originating from as many research institutes, universities and university hospitals will be featured. This year, Ascenion’s partner institutes contribute a record number of seven projects including diagnostic and therapeutic approaches against cancer, infection, atherosclerosis and kidney disease. The technologies are:
- Targeting host lipid homeostasis to augment anti-mycobacterial treatment (Research Center Borstel – Leibniz Lung Center)
- Preventing vascular calcification in Chronic Kidney Disease (CKD) (Charité Universitätsmedizin Berlin)
- Novel CAR-T against CXCR5 for treatment of non-Hodgkin lymphoma (Max Delbrück Center for Molecular Medicine)
- Novel labyrinthopeptins as anti-viral agents (Helmholtz Centre for Infection Research)
- Minigastrin analogs for enhanced cholecystokinin-2 receptor targeting and their theranostic use (Medical University of Innsbruck)
- Selective inhibitors of genotoxic stress-induced IKK/NF-κB pathways for cancer therapy (Max Delbrück Center for Molecular Medicine)
- Innovative biomarker for early prediction of atherosclerosis (Hannover Medical School)
A preview of all technologies selected for BioVaria 2019 is available online.
Further program highlights include a panel discussion on the “Development of ATMPs for Regenerative Medicine” and BioVaria’s dedicated Startup Pitch & Partner program. The expanded format of the Startup Pitch & Partner program provides attractive opportunities for entrepreneurs and venture capitalists, with interactive pitches, one-on-one mentoring sessions and speed dating between startups and investors. Based on last year’s success it attracted more applications from European startups than ever before. A preview of the startups selected for BioVaria 2019’s Startup Pitch & Partner program will soon be available online.
BioVaria is organised by Ascenion and 14 additional technology transfer organisations from five European nations.
BioVaria brings together Europe’s top scientists and technology transfer professionals with potential licensees and investors from the international biopharmaceutical industry.
Key features of BioVaria 2019:
- Unique gathering of Europe's top scientists, entrepreneurs, technology transfer professionals, investors and industry representatives
- Presentation of more than 60 licensable technologies and startups originating from public research institutions and universities across Europe
- Focus on patent-protected, commercially attractive opportunities covering therapeutics, diagnostics and research tools in the fields of cancer, infectious diseases, metabolism, autoimmune and neurodegenerative disorders, and in other disease areas
- Interactive format combining 10-min oral presentations with an interactive exhibition and plenty of networking opportunities
- Startup Pitch & Partner program with a competition for the BioVaria Startup Award, one-on-one mentoring and startup-investor speed dating
- Panel discussion on the “Development of ATMPs for Regenerative Medicine”
- Ample space to discuss scientific details face-to-face with the inventors and entrepreneurs
- Jointly organized by Ascenion and a selected group of leading European technology transfer organizations
Bavarian Ministry of Economic Affairs, Regional Development and Energy
BioM, Abbvie, Else Kröner-Fresenius-Stiftung, ISAR Bioscience, Johnson & Johnson Innovation, HERTIN & Partner, Kador & Partner, Vossius & Partner
24IP Law Group, Accelero Bioanalytics, Charles River, German Accelerator Life Sciences, IASON Consulting, LSI Life Science Inkubator, LSP, ttopstart, TVM Capital Life Science
Technology transfer partners:
Ascenion, Austria Wirtschaftsservice Gesellschaft, BayPAT, DKFZ - German Cancer Research Center, DZIF - German Center for Infection Research, EMBLEM Technology Transfer, IOCB Tech, Lead Discovery Center, LMU Munich, Max Planck Innovation, Netval, PROvendis, TechnologieAllianz, University of Pardubice, VIS
ASTP-Proton, BIO Deutschland, BioRN
Business Wire, Going Public, LABIOTECH.eu, transkript
Ascenion is an independent technology transfer company focussing on the life sciences. It is partner to over 30 research organizations, universities and university hospitals in Germany and Europe, including life-science institutes of the Helmholtz and Leibniz Associations, the Charité, the Hannover Medical School, the Medical University of Innsbruck and the University Medical Center Göttingen. Ascenion’s multidisciplinary, industry-experienced team works closely with its partners to tap the potential of their research by identifying promising results, obtaining patent protection, and turning pure science into applied technology. Particular strengths are spin-off support and project development, where early-stage projects are transformed into assets that attract potential investors and licensees. This has led to the founding of numerous new companies and the transfer of innovative medical approaches into approved drugs, changing the lives of thousands of patients. Profits from Ascenion’s operative business and exit proceeds flow via its parent company, the LifeScience Foundation for the Promotion of Science and Research, to fund further translational research at its partner institutes.
Further information at: www.ascenion.de
Stanislava Zollner, Corporate Communication, Ascenion GmbH
zollner(at)ascenion(dot)de, +49 89 3188140